GlassScriptPhysician profile
Carlos A Leon
NPI 1932131869
$4,660.20
in general payments reported to CMS, 2019-2025
41 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $250 · 2021: $505 · 2022: $450 · 2023: $1,022 · 2024: $878 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $445.09 | 2019-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $410.31 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $379.48 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $292.85 | 2019-2025 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $292.19 | 2020-2025 | Benlysta |
| Opko Pharmaceuticals, LLC | $260.76 | 2019-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $252.39 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $243.93 | 2024-2025 | Tarpeyo |
| Genentech USA, INC. | $237.70 | 2019 | |
| Horizon Therapeutics Plc | $197.20 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $177.60 | 2019-2024 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $176.16 | 2020-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $145.30 | 2021-2023 | |
| Bard Peripheral Vascular, INC. | $134.62 | 2019-2023 | Pristine, Wavelinq |
| Organogenesis INC. | $117.67 | 2020 |
Show all 37 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.